Clinical trial
Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines
NCT00240292 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00240292 |
|---|---|
| Title | Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines |
| Official title | A Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre, Phase III Study to Assess the Impact of Rosuvastatin Treatment for 26 Weeks (Titrated to a Maximum Dose of 40mg Once Daily) on Left Ventricular Function, Cytokines and Lipid Parameters in Patients With Established Systolic… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive |
| Intervention type | Drug |
| Interventions | Rosuvastatin |
| Enrollment | 160 |
| Start date | Feb 1, 2003 |
| First posted | Oct 18, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Australia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: